Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
RATIONALE: Studying samples of bone marrow from patients with Fanconi anemia and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to Fanconi anemia.
PURPOSE: This laboratory study is evaluating gene function in bone marrow cells from patients with Fanconi anemia and from healthy participants.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells|
- Comparison of Fanconi anemia (FA) hematopoietic cells vs normal hematopoietic cells [ Designated as safety issue: No ]
- Comparison of FA hematopoietic cells from children with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) vs children (siblings) with FA but without MDS/AML [ Designated as safety issue: No ]
- Comparison of FA cells from different complementation groups [ Designated as safety issue: No ]
|Study Start Date:||March 2002|
|Study Completion Date:||September 2007|
|Estimated Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
- Describe the complete hematopoietic transcriptomes of Fanconi cells of every common complementation group (e.g., A, C, G, and F) as well as transcriptomes of neoplastic cells derived from bone marrow of patients with Fanconi anemia.
- Define large-scale dynamic gene expression data in these patients.
OUTLINE: This is a multicenter study.
Patients and healthy volunteers undergo bone marrow aspiration or biopsy for biological studies. Samples are analyzed for gene expression profiles using microarray assays.
PROJECTED ACCRUAL: A total of 80 patients and 10 healthy volunteers will be accrued for this study.
|United States, Oregon|
|Knight Cancer Institute at Oregon Health and Science University|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Grover C. Bagby, MD||OHSU Knight Cancer Institute|